Canadian Sec - Delayed Quote CAD

Sona Nanotech Inc. (SONA.CN)

0.2800 0.0000 (0.00%)

At close: October 30 at 1:03:58 PM EDT

Sona Nanotech Announces Chief Technology Officer and Annual Options Grants

CNW Group 18d ago

SONA.CN
0.00%
SNANF
Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th

GlobeNewswire 1mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds

CNW Group 2mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors

CNW Group 4mo ago

SONA.CN
0.00%
CHRS

GSK.L
Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

CNW Group 5mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

CNW Group 6mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech appoints two oncologists to scientific advisory board

Proactive 6mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

CNW Group 6mo ago

SONA.CN
0.00%
SNANF
Sona Nanotech preclinical study shows tumor regression in colorectal cancer model

Proactive 6mo ago

SONA.CN
0.00%
Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

GlobeNewswire 1mo ago

ROVA.CN

AVCN.TO

AVCNF
Life Sciences Virtual Investor Forum Agenda Announced

GlobeNewswire 1mo ago

SONA.CN
0.00%
RAPH

SNANF
SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING

CNW Group 2mo ago

SONA.CN
0.00%
SNANF

U.S. markets closed

Sona Nanotech Inc. (SONA.CN)

Sona Nanotech Announces Chief Technology Officer and Annual Options Grants

Sona Nanotech to Present at the OTC Markets’ Life Sciences Virtual Investor Forum On September 17th

Sona Nanotech Closes Over-Subscribed Private Placement Financing to Raise $2,527,012 in Gross Proceeds

Sona Nanotech Appoints Seasoned Biotech Commercial Executive Michael A. Fleming to Board of Directors

Sona Nanotech Announces Clinical Strategy With Two THT Combination Therapy Studies In Melanoma

Sona Nanotech Showcases Cancer Therapy Results At Prestigious Industry Cancer Conferences

Sona Nanotech appoints two oncologists to scientific advisory board

Sona Nanotech Clinical Cancer Study Tissue Analysis Confirms Tumor Priming And Suggests Potential Immunotherapy Synergies

Sona Nanotech preclinical study shows tumor regression in colorectal cancer model

Life Sciences Virtual Investor Forum Presentations Now Available for On-Demand Viewing

Life Sciences Virtual Investor Forum Agenda Announced

SONA NANOTECH TO ARRANGE PRIVATE PLACEMENT FINANCING